Cintia Piccina
About Cintia Piccina
Cintia Piccina is a seasoned Chief Commercial Officer with over 20 years of experience in the pharmaceutical and biotech industries, currently serving at Adaptimmune. She has held significant roles at various leading companies, including AlloVir, Novartis, and bluebird bio, where she has developed and executed commercial strategies for innovative therapies.
Work at Adaptimmune
Cintia Piccina currently serves as the Chief Commercial Officer (CCO) at Adaptimmune, a position she has held since 2024 in Cambridge, Massachusetts. In this role, she is responsible for overseeing the global commercial strategy for the company's innovative therapies. Previously, she held the same title at Adaptimmune from 2022 to 2023 in Philadelphia, Pennsylvania, where she contributed to the development of commercialization capabilities.
Education and Expertise
Cintia Piccina holds a Doctorate in Pharmacy and Biochemistry (PharmD) from the University of São Paulo, which she completed from 1991 to 1995. She also earned an MBA in Marketing Administration from the Escola Superior de Propaganda e Marketing between 1996 and 1998. Additionally, she participated in the Women in Boards program at Wharton Executive Education in 2023. Piccina is fluent in English, Portuguese, and Spanish, and has over 20 years of experience in the pharmaceutical and biotech industries.
Background
Cintia Piccina has a diverse background in the pharmaceutical sector, having worked at several leading companies. She spent over 20 years at Novartis, where she held various roles, including VP of US Oncology Lung and Rare Diseases Business Franchise and Head of Sales for Neurosciences. She also served as SVP Global Commercial & US General Manager at 2seventy bio and SVP, Global Commercial Oncology & US General Manager at bluebird bio, where she led the launch of the first cell therapy product in multiple myeloma.
Achievements
Throughout her career, Cintia Piccina has demonstrated a proven track record in developing and implementing commercial and market access strategies. She has successfully forged strategic partnerships with key stakeholders and led the launch and growth of innovative therapies across various therapeutic areas, including Oncology, Immunology, and Rare Diseases. Her leadership at AlloVir focused on building the company's commercialization capabilities for allogeneic cell therapy products.